Kaneka America Corp LIPOSORBER System, Model: LA-15, consisting of: Apheresis machine, product# 101445 model: MA-03, and disposables (product#, model) [#101447, KP-05 Sulflux Plasma Separator], [#101473, HDE KP-05 Sulflux Plasma Separator], [#101785, LA-15 (AU) LDL Adsorption Column (Luer Lock Type)], [#101786, NK-M3R(UL) Tubing (Luer Lock Type)], [#101788, HDE LA-15(AU) LDL Adsorption Column (Luer Lock Type)], [#101789, HDE NK-M3R(UL) Tubing (Luer Lock Type)]. Associated labeling: 1) Instructions Recall
Check Your Product
According to the U.S. Food and Drug Administration (FDA)
Product
LIPOSORBER System, Model: LA-15, consisting of: Apheresis machine, product# 101445 model: MA-03, and disposables (product#, model) [#101447, KP-05 Sulflux Plasma Separator], [#101473, HDE KP-05 Sulflux Plasma Separator], [#101785, LA-15 (AU) LDL Adsorption Column (Luer Lock Type)], [#101786, NK-M3R(UL) Tubing (Luer Lock Type)], [#101788, HDE LA-15(AU) LDL Adsorption Column (Luer Lock Type)], [#101789, HDE NK-M3R(UL) Tubing (Luer Lock Type)]. Associated labeling: 1) Instructions
Brand
Kaneka America Corp
Lot Codes / Batch Numbers
All product lot and UDI numbers are affected.
Products Sold
All product lot and UDI numbers are affected.
Kaneka America Corp is recalling LIPOSORBER System, Model: LA-15, consisting of: Apheresis machine, product# 101445 model: MA-03, a due to Labeling change to due to the risk of severe anaphylactoid reactions including shock in patients treated with the Liposorber LA-15 LDL Adsorption Colu. Based on FDA medical device recall database.
Summary derived from FDA notice
Reason for Recall
As stated by FDA
Labeling change to due to the risk of severe anaphylactoid reactions including shock in patients treated with the Liposorber LA-15 LDL Adsorption Column under concomitant ACE inhibitor medication treatment.
Recommended Action
Per FDA guidance
On 02/17/2022 a recall notification letter with revised labeling was emailed regarding contraindication in patients who are being treated with angiotensin-converting enzyme (ACE) inhibitors. Customers are to locate, destroy and replace all operator's manuals, patient guides, and IFUs with those attached to the recall notice, ensuring they are distributed to all end users. All device model, lot, and UDI numbers for systems and disposables are affected. Submit the Acknowledgement and Receipt Form to Kaneka Medical America, LLC via email. If you have any question or concerns about this recall please contact Kaneka Medical America LLC Monday through Friday, 8:00 AM to 4:30 PM, Eastern Time, at: Phone: (212) 705-4355, Email: Ahmad.Al-Sattari@kaneka.com
Verify this information on the official source
For complete details and official instructions, check the U.S. Food and Drug Administration (FDA) directly.
View official FDA recall noticeDistribution
As reported by FDA
AL, AZ, CA, CO, CT, DE, FL, GA, IL, IN, KS, ME, MD, MA, MI, MN, MS, MO, NE, NH, NJ, NY, NC, OH, OK, OR, PA, SC, TN, TX, UT, VA, WA, WI
Page updated: Jan 10, 2026